Inotiv Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Inotiv Inc (NOTV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Inotiv Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 507M vs 37,761M combined for tracked competitors (1.3% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-7.2% annualized vs trailing 12 months), vs holding steady (-0.5%) for its tracked peer group.
- Growth: Inotiv Inc generated -5.4% revenue growth year over year in Q2 2026, vs 7.7% for its tracked competitors combined.
- Profitability: Its -27.6% net margin compares with 7.1% for the peer group.
- Peer revenue share: Inotiv Inc accounted for 1.2% of combined revenue among its tracked peer group, down from 1.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.25M compares with $0.20M for the peer group (1.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NOTV Sales vs. its Competitors, Q2 2026
Inotiv Inc reported revenue contraction of 5.37 % year on year in Q2 2026, below its competitors' combined revenue growth of 7.73 %.
With a net margin of -27.60 %, Inotiv Inc reported lower profitability than its competitors (7.05 %).
Inotiv Inc generated 1.24 % of the combined sales of its peer group, down from 1.41 % a year earlier.
Inotiv Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Inotiv Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Inotiv Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Inotiv Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs -5.4% for Inotiv Inc. Inotiv Inc's share of combined industry revenue moved from 0.23% to 0.20%, a loss of 0.02 percentage points.
Inotiv Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Inotiv Inc | No | Yes | No | Yes |
| Competitors combined (4) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) | 25.00 % (2 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NOTV Stock Performance relative to its Competitors
NOTV Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Charles River Laboratories International inc | 282.9% | Outperformed |
| 2 | Iqvia Holdings Inc | 282.9% | Outperformed |
| 3 | Medpace Holdings Inc | 282.9% | Outperformed |
| 4 | Labcorp Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Inotiv Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Inotiv Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Inotiv Inc | 0.38 | 507.36 |
| Iqvia Holdings Inc | 46,010.71 | 16,632.00 |
| Labcorp Holdings Inc | 25,384.74 | 14,348.00 |
| Medpace Holdings Inc | 17,587.55 | 2,782.29 |
| Charles River Laboratories International inc | 14,146.51 | 3,998.99 |
| SUBTOTAL | 103,129.89 | 38,268.63 |
Sources: Inotiv Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Inotiv Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Inotiv Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Inotiv Inc | Research Models and Services 59.98 % |
| Iqvia Holdings Inc | Research and Development Solutions 58.90 % |
| Labcorp Holdings Inc | Diagnostics 78.08 % |
| Medpace Holdings Inc | Reportable 100.00 % |
| Charles River Laboratories International inc | Discovery and Safety Assessment 59.94 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Inotiv Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Inotiv Inc | 0 | 247,975 | -42,509 |
| Iqvia Holdings Inc | 46,011 | 178,839 | 14,914 |
| Labcorp Holdings Inc | 25,385 | 204,971 | 14,336 |
| Medpace Holdings Inc | 17,588 | 448,756 | 79,274 |
| Charles River Laboratories International inc | 14,147 | 202,994 | -11,995 |
| PEERS TOTAL | 103,130 | 199,901 | 14,006 |
Inotiv Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Inotiv Inc | United States 88.12 % |
| Iqvia Holdings Inc | Americas 48.17 % |
| Charles River Laboratories International inc | United States 54.61 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Inotiv Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 42 companies in Inotiv Inc's industry classification, broader than the peer set above. Market cap in millions of $.Inotiv Inc ranks #0 of 42 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 860, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Natera Inc | 58,913 | 16.93 % |
| 2 | Iqvia Holdings Inc | 45,638 | 13.12 % |
| 3 | Ge Healthcare Technologies Inc | 30,422 | 8.74 % |
| 4 | Quest Diagnostics Inc | 26,362 | 7.58 % |
| 5 | Incyte Corporation | 1,234 | 5.2% |
| 6 | Labcorp Holdings Inc | 1,234 | 5.2% |
| 7 | Guardant Health Inc | 1,234 | 5.2% |
| 8 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 0 | Inotiv Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Inotiv Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-27.
Inotiv Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (58 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 65.33 % | 43.57 % (avg) | +21.8 pp |
| Operating Margin | -9.48 % | industry median | +16.5 pp |
| EBITDA Margin | -6.30 % | -4.90 % (avg) | -1.4 pp |
| Capital Intensity (Capex / Revenue) | 2.75 % | 9.54 % (avg) | -6.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Inotiv Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (58 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.0x | - |
| EV / EBITDA | - | 18.0x | - |
| P/B | 0.1x | 2.9x | -2.8x |
| Return on Equity | -74.67 % | industry aggregate | -83.67 % |
| Return on Invested Capital | -11.25 % | -4.04 % (avg) | -7.21 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Inotiv Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 26.23 % | 61.89 % | 36.58 % | 138.30 % | 275.93 % | -0.18 % | -18.81 % | 8.19 % |
| Operating Margin | 0.15 % | -2.53 % | -3.10 % | -25.19 % | -54.66 % | -0.04 % | -19.48 % | -6.17 % |
| Return on Invested Capital | 0.17 % | -3.40 % | -5.10 % | -7.42 % | -23.60 % | -0.03 % | -13.88 % | -5.45 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Inotiv Inc's Strategic Group Map
Every company in Inotiv Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Inotiv Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Inotiv Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 860 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.75 % vs industry average 9.54 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Inotiv Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Inotiv Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Inotiv Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Inotiv Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Inotiv Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 16.5 points above the industry median.
Weaknesses
- Return on equity 83.7 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-7.2% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Inotiv Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Inotiv Inc | 0.03 | 0.38 | 3.47 |
| Iqvia Holdings Inc | 0.24 | 0.76 | 2.47 |
| Labcorp Holdings Inc | 0.22 | 1.61 | 0.66 |
| Medpace Holdings Inc | 0.36 | 0.72 | - |
| Charles River Laboratories International inc | 0.18 | 1.34 | 0.78 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Inotiv Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Inotiv Inc | Q1 2026 | -5.4 % | - |
| Iqvia Holdings Inc | Q1 2026 | +8.4 % | +10.4 % |
| Labcorp Holdings Inc | Q2 2026 | +5.8 % | +25.5 % |
| Medpace Holdings Inc | Q2 2026 | +17.2 % | +34.5 % |
| Charles River Laboratories International inc | Q2 2026 | -2.7 % | - |
| PEERS TOTAL | +6.5 % | +7.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Inotiv Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Inotiv Inc | Q1 2026 | +1.2 % | -61.6 % |
| Iqvia Holdings Inc | Q1 2026 | +10.5 % | -10.6 % |
| Labcorp Holdings Inc | Q2 2026 | +5.6 % | +68.9 % |
| Medpace Holdings Inc | Q2 2026 | +19.5 % | +291.2 % |
| Charles River Laboratories International inc | Q2 2026 | - | -11.9 % |
Inotiv Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Inotiv Inc | - | - | - |
| Iqvia Holdings Inc | 4.74% | 5.95% | 22.15% |
| Labcorp Holdings Inc | 5.40% | 6.11% | 11.58% |
| Medpace Holdings Inc | 24.84% | 35.54% | 110.15% |
| Charles River Laboratories International inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Inotiv Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Inotiv Inc | - | 0.00 |
| Iqvia Holdings Inc | 33.70 | 2.77 |
| Labcorp Holdings Inc | 25.63 | 1.77 |
| Medpace Holdings Inc | 36.30 | 6.32 |
| Charles River Laboratories International inc | - | 3.54 |
| PEERS AVERAGE | 40.31 | 2.69 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.